Daniel M. Geynisman Takes Helm as Editor-in-Chief of JNCCN

National Comprehensive Cancer Network

PLYMOUTH MEETING, PA — Daniel M. Geynisman, MD, has been named the new Editor-in-Chief of the Journal of the National Comprehensive Cancer Network (JNCCN). Dr. Geynisman, a seasoned oncologist with a rich history at the National Comprehensive Cancer Network (NCCN), takes on this pivotal role after serving as the medical oncology section editor for Urologic Oncology: Seminars and Original Investigations since 2018.

“We are thrilled to welcome Dr. Geynisman into this crucial position for JNCCN,” said Crystal S. Denlinger, MD, Chief Executive Officer of NCCN. “Our journal fills many important roles when it comes to oncology knowledge sharing. In addition to publishing exclusive insights and updates for the NCCN Guidelines, JNCCN publishes rigorous health services research, original investigations, and reviews addressing all aspects of cancer care delivery. Its impact factor grows every year—currently calculated at 13.4, placing it in the top 10 percent of cancer-related publications. We look forward to seeing what new heights we can reach under Dan’s leadership.”

JNCCN is dedicated to improving cancer care standards worldwide. The journal focuses on high-quality original research in health services, outcomes, quality improvement, and policy. It also serves as a trusted resource for information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

Dr. Geynisman expressed his honor at being appointed Editor-in-Chief. “Fox Chase Cancer Center was a founding Member Institution for NCCN, and the opportunity to lead JNCCN is an enormous privilege. I am excited to expand upon the legacy of practice setting guidelines and outstanding research contributions published and look forward to working with the editorial board and journal staff to continue to build and grow JNCCN as a premier destination for oncology research.”

READ:  Brandwidth Solutions Launches Custom Marketing ROI Platform

Dr. Geynisman brings extensive experience to the role. He has authored over 130 peer-reviewed publications and serves as the Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center. His work with NCCN includes membership on several guideline panels and participation in grant selection committees. He has also reviewed abstracts for the NCCN Annual Conference and has received NCCN research grants through the Oncology Research Program.

He succeeds Margaret Tempero, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, who now leads the Cancer Early Detection Initiative at UCSF. During her tenure, Dr. Tempero emphasized molecular medicine and health services research. She oversaw several redesigns of the journal’s digital and print formats, moving towards increased online content with a modern look. Her legacy can be explored in depth in the March issue of JNCCN.

Advancing Oncology: Dr. Geynisman’s Editorial Leadership at JNCCN

The appointment of Dr. Geynisman as Editor-in-Chief marks a significant step for JNCCN. His leadership is expected to drive further innovation and excellence in oncology research. This transition is crucial as the journal continues to support the evolving needs of cancer care professionals and patients globally.

Dr. Geynisman’s background in genitourinary oncology and his extensive publication record highlight his expertise and commitment to advancing cancer treatment. His role will likely enhance the journal’s reputation and influence in the oncology field.

For healthcare professionals, JNCCN remains a vital source of the latest research and clinical guidelines. As the journal grows under Dr. Geynisman’s leadership, it will continue to play a key role in shaping cancer care practices and policies.

READ:  Hartford Funds Names New President as Jim Davey Steps Down

From a broader perspective, the advancements and insights published in JNCCN contribute to global efforts in cancer treatment and prevention. High-impact research can lead to better patient outcomes, more effective treatments, and improved healthcare policies.

In conclusion, Dr. Geynisman’s appointment as Editor-in-Chief of JNCCN is a promising development for the oncology community. His leadership is poised to guide the journal to new heights, ensuring it remains at the forefront of cancer research and care.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.